Browse Prior Art Database

Oral Pharmaceutical Formulations for bone resorption inhibitor

IP.com Disclosure Number: IPCOM000011781D
Publication Date: 2003-Mar-14
Document File: 1 page(s) / 21K

Publishing Venue

The IP.com Prior Art Database

This text was extracted from a Microsoft Word document.
At least one non-text object (such as an image or picture) has been suppressed.
This is the abbreviated version, containing approximately 100% of the total text.

Oral Pharmaceutical Formulations for Bone Resorption Inhibitor

Sustained, controlled or immediate release oral dosage forms capable of releasing the active pharmaceutical ingredient represented by the chemical formula shown in Figure 1, optionally in the form of its monosodium salt trihydrate, to human patients immediately or over extended periods following administration may contain the following active and inactive ingredients: 15% to 25% of the active pharmaceutical ingredient represented by the chemical formula shown in Figure 1, optionally in the form of its monosodium salt trihydrate, 20% to 30% of a naturally occurring clathrate e.g. betadex, 30% to 50% of a calcium hydrogen phosphate, 5%-15% of a sodium starch glycolate and optionally other conventional tabletting excipients selected from cross-linked cyclic amide polymers, known lubricants, opacifiers, glidants and/or anti-caking agents in amounts from 0.1% to 2%.� All ranges are approximate and are expressed as percentage of the total dosage form by weight.�

Said dosage forms may be administered or further processed in granulate, tablet or powder form as solid solutions, solid dispersions or mixtures thereof.� Any known and as-yet undisclosed formulation methods may be used as-is or adapted in any manner to arrive at the formulations disclosed herein.�

Fig. 1

Disclosed Anonymously